How should we proceed with disease-modifying treatments for multiple sclerosis?
Andersson
P B
PB
University of California San Francisco/Mt Zion Multiple Sclerosis Center 94115, USA.
Waubant
E
E
Goodkin
D E
DE
D002986:Clinical Trials as Topic; D018450:Disease Progression; D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use
D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a